Chemotherapy: Open Access
Open Access
ISSN: 2167-7700
+44 1223 790975
ISSN: 2167-7700
+44 1223 790975
Pin Wang, Jian-Hua Mao, Bo Hang
In this commentary, we discuss our recently published research on the development of a clinically applicable 53-gene prognostic assay that can predict chemotherapy benefit in gastric cancer 1 and related clinical significance. This is a reliable high-throughput mRNA hybridization-based assay, providing a solution to better measure the 53-gene expression in formalin-fixed paraffin-embedded (FFPE) tissues from patients. The predictive power of the 53-gene signature in patients with gastric cancer was successfully validated in three hospital cohorts and patients with good prognostic scores exhibited a significantly better 5-year overall survival (OS) rate from adjuvant FOLFOX (leucovorin, fluorouracil, and oxaliplatin) chemotherapy after surgery than from other chemotherapies. Future work should focus on prospective clinical trials to fully deploy this score system into clinical utility.
Published Date: 2020-11-17; Received Date: 2020-11-26